Changing landscape of frontline therapy in chronic lymphocytic leukemia

被引：2

作者：

Bhat, Seema A. ^{[1
]}

Woyach, Jennifer A. ^{[1
]}

机构：

[1] Ohio State Univ, Comprehens Canc Ctr, 455D Wiseman Hall CCC,410 W 12th Ave, Columbus, OH 43210 USA

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 03期

关键词：

Frontline therapy; CLL; chronic lymphocytic leukemia; BRUTONS TYROSINE KINASE; PREVIOUSLY UNTREATED PATIENTS; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; OPEN-LABEL; FCR CHEMOIMMUNOTHERAPY; INITIAL THERAPY; PHASE-III; IBRUTINIB; RITUXIMAB; VENETOCLAX;

D O I：

10.1080/10428194.2019.1688321

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The therapeutic landscape for chronic lymphocytic leukemia has significantly evolved in recent years as our understanding of the biology of this disease has advanced. Chemoimmunotherapy has been the standard frontline treatment for patients of all age groups with chronic lymphocytic leukemia over the last decade. B-cell receptor signaling pathway plays a central role in the pathogenesis of chronic lymphocytic leukemia. The advent of novel small-molecule therapy for the treatment of chronic lymphocytic leukemia targeting the B-cell receptor signaling pathway has dramatically changed the therapeutic landscape with recent studies establishing ibrutinib, a Bruton's tyrosine kinase inhibitor, as the frontline treatment of choice regardless of patient's age, performance status or risk-category. Although these current advances along with the approval of other newer agents for the treatment of chronic lymphocytic leukemia is a significant step forward, newer challenges have emerged on how to best utilize these new treatment options.

引用

页码：525 / 535

页数：11

共 68 条

[1]

[Anonymous], 1990, Blood, V75, P1414

[2]

[Anonymous], Prostate Cancer (Ver

[3]

[Anonymous], 2009, BLOOD, DOI DOI 10.1182/BLOOD.V114.22.536.536

[4] Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801 [J].

Barr, Paul M. ;

Li, Hongli ;

Burack, Richard ;

LeBlanc, Michael ;

Smith, Sonali M. ;

Gopal, Ajay K. ;

Floyd, Justin D. ;

Persky, Daniel O. ;

Press, Oliver ;

Fisher, Richard I. ;

Friedberg, Jonathan W. .

BLOOD, 2016, 128 (22)

[5] Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes [J].

Benjamini, Ohad ;

Jain, Preetesh ;

Trinh, Long ;

Qiao, Wei ;

Strom, Sara S. ;

Lerner, Susan ;

Wang, Xuemei ;

Burger, Jan ;

Ferrajoli, Alessandra ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Wierda, William ;

Estrov, Zeev ;

Keating, Michael .

LEUKEMIA & LYMPHOMA, 2015, 56 (06) :1643-1650

[6] Survival of leukemic B cells promoted by engagement of the antigen receptor [J].

Bernal, A ;

Pastore, RD ;

Asgary, Z ;

Keller, SA ;

Cesarman, E ;

Liou, HC ;

Schattner, EJ .

BLOOD, 2001, 98 (10) :3050-3057

[7] Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia [J].

Brown, Jennifer R. ;

Kay, Neil E. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) :2889-+

[8] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[9] Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia [J].

Burger, Jan A. ;

Sivina, Mariela ;

Jain, Nitin ;

Kim, Ekaterina ;

Kadia, Tapan ;

Estrov, Zeev ;

Nogueras-Gonzalez, Graciela M. ;

Huang, Xuelin ;

Jorgensen, Jeffrey ;

Li, Jianling ;

Cheng, Mei ;

Clow, Fong ;

Ohanian, Maro ;

Andreeff, Michael ;

Mathew, Thomas ;

Thompson, Philip ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Wierda, William G. ;

Ferrajoli, Alessandra ;

Keating, Michael J. .

BLOOD, 2019, 133 (10) :1011-1019

[10] Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition [J].

Burger, Jan A. ;

Landau, Dan A. ;

Taylor-Weiner, Amaro ;

Bozic, Ivana ;

Zhang, Huidan ;

Sarosiek, Kristopher ;

Wang, Lili ;

Stewart, Chip ;

Fan, Jean ;

Hoellenriegel, Julia ;

Sivina, Mariela ;

Dubuc, Adrian M. ;

Fraser, Cameron ;

Han, Yulong ;

Li, Shuqiang ;

Livak, Kenneth J. ;

Zou, Lihua ;

Wan, Youzhong ;

Konoplev, Sergej ;

Sougnez, Carrie ;

Brown, Jennifer R. ;

Abruzzo, Lynne V. ;

Carter, Scott L. ;

Keating, Michael J. ;

Davids, Matthew S. ;

Wierda, William G. ;

Cibulskis, Kristian ;

Zenz, Thorsten ;

Werner, Lillian ;

Dal Cin, Paola ;

Kharchencko, Peter ;

Neuberg, Donna ;

Kantarjian, Hagop ;

Lander, Eric ;

Gabriel, Stacey ;

O'Brien, Susan ;

Letai, Anthony ;

Weitz, David A. ;

Nowak, Martin A. ;

Getz, Gad ;

Wu, Catherine J. .

NATURE COMMUNICATIONS, 2016, 7

← 1 2 3 4 5 6 7 →